Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

被引：9

作者：

Nizam, Amanda ^{[1
]}

Jindal, Tanya ^{[2
]}

Jiang, Cindy Y. ^{[3
]}

Alhalabi, Omar ^{[4
]}

Bakaloudi, Dimitra Rafailia ^{[5
]}

Talukder, Rafee ^{[6
]}

Davidsohn, Matthew P. ^{[7
]}

Nguyen, Charles B. ^{[8
]}

Oh, Eugene ^{[9
]}

Taylor, Amy K. ^{[10
]}

Lemke, Emily ^{[11
]}

Kilari, Deepak ^{[12
]}

Hoimes, Christopher J. ^{[13
]}

Emamekhoo, Hamid ^{[14
]}

Gupta, Shilpa ^{[15
]}

Bellmunt, Joaquim ^{[16
]}

Grivas, Petros ^{[17
,18
]}

Campbell, Matthew T. ^{[19
]}

Alva, Ajjai Shivaram ^{[20
]}

Koshkin, Vadim S. ^{[21
]}

机构：

[1] Cleveland Clin, Cleveland, OH USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA

[5] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA

[6] Baylor Coll Med, Houston, TX USA

[7] Albert Einstein Coll Med, New York, NY USA

[8] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA

[9] Univ Michigan, Sch Med, Ann Arbor, MI USA

[10] Univ Wisconsin Hosp & Clin, Madison, WI USA

[11] Med Coll Wisconsin, Milwaukee, WI USA

[12] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA

[13] Duke Univ, Duke Canc Inst, Durham, NC USA

[14] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[16] Dana Farber Canc Inst, Boston, MA USA

[17] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[18] Fred Hutchinson Canc Ctr, Seattle, WA USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA

[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-183-138-12099; 613-135-2370-7650-2700; 6; 5; 3224; 1880; 62; 295; 3; 1; 38092-23700;

D O I：

10.1200/JCO.2024.42.4_suppl.537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：537 / 537

页数：1

共 50 条

[1] Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, Tanya
Kilari, Deepak
Alhalabi, Omar
Nizam, Amanda
Khaki, Ali Raza
Basu, Arnab
Barata, Pedro C.
Bilen, Mehmet Asim
Shah, Sumit
Zakharia, Yousef
Milowsky, Matthew I.
Bellmunt, Joaquim
Emamekhoo, Hamid
Davis, Nancy B.
Grivas, Petros
Gupta, Shilpa
Hoimes, Christopher J.
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[2] Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, Tanya
Zhang, Li
Jiang, Cindy
Kilari, Deepak
Alhalabi, Omar
Nizam, Amanda
Basu, Arnab
Bilen, Mehmet Asim
Zakharia, Yousef
Milowsky, Matthew I.
Shah, Sumit
Hoimes, Christopher J.
Davis, Nancy B.
Gupta, Shilpa
Emamekhoo, Hamid
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
Nizam, A.
Zhang, L.
Jindal, T.
Nguyen, C. B.
Alhalabi, O.
Basu, A.
Evans, S. P.
Hoimes, C. J.
Zakharia, Y.
Milowsky, M. I.
Kilari, D.
Shah, S. A.
Davis, N. B.
Emamekhoo, H.
Gupta, S.
Bellmunt, J.
Grivas, P.
Campbell, M. T.
Alva, A.
Koshkin, V. S.
ANNALS OF ONCOLOGY, 2023, 34 : S1219 - S1219
[4] Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.
Jindy, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Nguyen, Charles B.
Nizam, Amanda
Basu, Arnab
Bilen, Mehmet Asim
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Emamekhoo, Hamid
Hoimes, Christopher J.
Khaki, Ali Raza
Gupta, Shilpa
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 652 - 652
[5] Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, Tanya
Jiang, Cindy
Alhalabi, Omar
Bakaloudi, Dimitra Rafailia
Talukder, Rafee
Davidsohn, Matthew
Nizam, Amanda
Taylor, Amy K.
Nguyen, Charles B.
Kilari, Deepak
Pywell, Cameron
Davis, Nancy B.
Emamekhoo, Hamid
Sonpavde, Guru P.
Gupta, Shilpa
Bellmunt, Joaquim
Grivas, Petros
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[6] Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.
Jindal, Tanya
Alhalabi, Omar
Nguyen, Charles B.
Bakaloudi, Dimitra Rafailia
Nizam, Amanda
Bilen, Mehmet Asim
Basu, Arnab
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Shah, Sumit
Emamekhoo, Hamid
Grivas, Petros
Hoimes, Christopher J.
Gupta, Shilpa
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 651 - 651
[7] Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
Koshkin, Vadim S.
Henderson, Nicholas
Kilari, Deepak
Jindal, Tanya
Alhalabi, Omar
Freeman, Dory
Basu, Arnab
Barata, Pedro C.
Bilen, Mehmet Asim
Zakharia, Yousef
Emamekhoo, Hamid
Shah, Sumit
Milowsky, Matthew I.
Davis, Nancy B.
Gupta, Shilpa
Hoimes, Christopher J.
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
Vlachou, Evangelia
Elias, Roy
Hahn, Noah M.
Mcconkey, David James
Johnson, Burles Avner
Hoffman-Censits, Jean H.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 570 - 570
[9] Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
Minato, Akinori
Furubayashi, Nobuki
Tomoda, Toshihisa
Masaoka, Hiroyuki
Song, Yoohyun
Hori, Yoshifumi
Kiyoshima, Keijiro
Negishi, Takahito
Kuroiwa, Kentaro
Seki, Narihito
Tomisaki, Ikko
Nakamura, Motonobu
Harada, Kenichi
Fujimoto, Naohiro
ANTICANCER RESEARCH, 2024, 44 (08) : 3419 - 3426
[10] Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan
Hara, Takuto
Matsushita, Yuto
Harada, Kenichi
Fujimoto, Naohiro
Fujisawa, Masato
Miyake, Hideaki
INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (06) : 696 - 698

← 1 2 3 4 5 →